PE20090060A1 - ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR - Google Patents

ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR

Info

Publication number
PE20090060A1
PE20090060A1 PE2008000503A PE2008000503A PE20090060A1 PE 20090060 A1 PE20090060 A1 PE 20090060A1 PE 2008000503 A PE2008000503 A PE 2008000503A PE 2008000503 A PE2008000503 A PE 2008000503A PE 20090060 A1 PE20090060 A1 PE 20090060A1
Authority
PE
Peru
Prior art keywords
alkyl
kinase
mtor inhibitors
imidazolopyrimidine
morfolin
Prior art date
Application number
PE2008000503A
Other languages
English (en)
Inventor
Matthew Gregory Bursavich
Aranapakam Mudumbai Venkatesan
Pawel Wojciech Nowak
Sabrina Lombardi
Adam Matthew Gilbert
Christoph Martin Dehnhardt
Santos Osvaldo Dos
Santos Efren Guillermo Delos
Natasja Brooijmans
Semiramis Ayral-Kaloustian
Zecheng Chen
Jeroen Cunera Verheijen
Joshua Kaplan
Arie Zask
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20090060A1 publication Critical patent/PE20090060A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

SE REFIERE A COMPUESTOS ANALOGOS DE IMIDAZOLOPIRIMIDINA DE FORMULA Ib, DONDE R1 ES N-MORFOLINILO O N-TIOMORFOLINILO; R2 ES ALQUENILO C2-C10, ALQUINILO C2-C10, ARILO C6-C14 O HETEROARILO C1-C9; R3 ES H, ALQUILO C1-C6, HETEROARILO C1-C9, CARBOCICLO C3-C8, HETEROCICLO BICICLICO DE 3 A 7 MIEMBROS, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, ALQUENILO C2-C10, ALQUINILO C2-C10 O (ARILO C6-C14)ALQUILO. SON SELECCIONADOS 6-MORFOLIN-4-IL-2-(2-TIENIL)-9H-PURINA, 2-[3-(3,5-DIMETOXI-BENCILOXI)-FENIL]-6-MORFOLIN-4-IL-9H-PURINA, ENTRE OTROS. SE REIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA QUE ADEMAS PUEDE CONTENER UN SEGUNDO COMPUESTO, TAL COMO AVASTINA, PROCARBAZINA, TAXOL, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON PI3K Y mTOR, TALES COMO EL CANCER
PE2008000503A 2007-03-21 2008-03-19 ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR PE20090060A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91930007P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
PE20090060A1 true PE20090060A1 (es) 2009-01-18

Family

ID=39535224

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000503A PE20090060A1 (es) 2007-03-21 2008-03-19 ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR

Country Status (13)

Country Link
US (1) US20080233127A1 (es)
EP (1) EP2125815A2 (es)
JP (1) JP2010522209A (es)
CN (1) CN101730697A (es)
AR (1) AR065813A1 (es)
AU (1) AU2008228758A1 (es)
BR (1) BRPI0809140A2 (es)
CA (1) CA2681326A1 (es)
CL (1) CL2008000790A1 (es)
MX (1) MX2009010067A (es)
PE (1) PE20090060A1 (es)
TW (1) TW200902531A (es)
WO (1) WO2008116129A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE456836T1 (de) * 1996-09-04 2010-02-15 Intertrust Tech Corp Zuverlässige infrastrukturhilfssysteme, verfahren und techniken für sicheren elektronischen handel, elektronische transaktionen, handelsablaufsteuerung und automatisierung, verteilte verarbeitung und rechteverwaltung
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
JP5479346B2 (ja) 2007-10-05 2014-04-23 ベラステム・インコーポレーテッド ピリミジン置換プリン誘導体
CA2703138A1 (en) * 2007-10-26 2009-04-30 F. Hoffmann-La Roche Ag Purine derivatives useful as pi3 kinase inhibitors
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック， インコーポレイテッド プリンｐｉ３ｋ阻害剤化合物および使用方法
JP2011529920A (ja) * 2008-07-31 2011-12-15 ジェネンテック， インコーポレイテッド ピリミジン化合物、組成物及び使用方法
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
ES2529205T3 (es) 2009-03-13 2015-02-17 Cellzome Limited Derivados de pirimidina como inhibidores de mTOR
EP2411387B1 (en) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MX2011010332A (es) 2009-04-03 2011-11-29 S Bio Pte Ltd Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
JPWO2010125799A1 (ja) 2009-04-27 2012-10-25 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有するウレア誘導体
EP2435438A1 (en) * 2009-05-27 2012-04-04 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG176959A1 (en) * 2009-06-24 2012-01-30 Genentech Inc Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
ES2706185T3 (es) 2009-07-07 2019-03-27 Mei Pharma Inc Pirimidinil y 1,3,5-triazinil bencimidazoles y sus usos en la terapia contra el cáncer
US8288381B2 (en) * 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
KR101447789B1 (ko) * 2009-11-12 2014-10-06 에프. 호프만-라 로슈 아게 Ｎ-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
ES2535116T3 (es) 2010-03-04 2015-05-05 Cellzome Limited Derivados de urea sustituida con morfolino como inhibidores de mtor
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
MX2013000389A (es) 2010-07-14 2013-03-08 Hoffmann La Roche Compuestos de purina selectivos para fosfatidilinositol 3-cinasa p110 delta, y metodods de uso.
WO2012037226A1 (en) * 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
PT2651951E (pt) 2010-12-16 2015-01-14 Hoffmann La Roche Compostos tricíclicos do inibidor pi3k e processos para a sua utilização
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR101940831B1 (ko) 2011-03-28 2019-01-21 메이 파마, 아이엔씨. (알파-치환된 아르알킬아미노 및 헤테로아릴알킬아미노)피리미딘일 및 1,3,5-트라이아진일 벤즈이미다졸, 이들을 함유하는 약학 조성물, 및 증식성 질병의 치료에 사용하기 위한 이들 화합물
WO2012136622A1 (en) 2011-04-04 2012-10-11 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
MX2020004502A (es) 2011-09-02 2022-01-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k).
RU2616619C2 (ru) 2011-09-21 2017-04-18 Селлзоум Лимитед Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor
AU2012320465B2 (en) 2011-10-07 2016-03-03 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
US8906910B2 (en) 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
BR112014028881A2 (pt) 2012-05-23 2017-06-27 Hoffmann La Roche populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CR20170389A (es) 2015-02-27 2018-01-26 Incyte Corp Sales de inhibidor de p13k y procesos de preparación
PL3277682T3 (pl) 2015-03-30 2019-09-30 Daiichi Sankyo Company, Limited Pochodne 6-morfolinylo-2-pirazolylo-9h-puryny i ich zastosowanie jako inhibitory pi3k
WO2016169417A1 (zh) * 2015-04-21 2016-10-27 成都金瑞长青生物科技有限公司 嘌呤基-n-羟基嘧啶甲酰胺衍生物及其制备方法和用途
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US11208442B2 (en) 2016-12-02 2021-12-28 Daiichi Sankyo Company, Limited Endo-beta-N-acetylglucosaminidase
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. POLYTHERAPY
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CA3072476A1 (en) 2017-08-14 2019-02-21 Mei Pharma, Inc. Combination therapy
CN112707907B (zh) * 2019-10-24 2023-05-23 张飞 嘌呤衍生物及其中间体与制备抗癌症药物的应用
CN111875606B (zh) * 2020-07-20 2023-04-07 武汉工程大学 一种基于虚拟对接获得的嘌呤类化合物及其制备方法和应用
CN113116895B (zh) * 2020-12-31 2023-08-18 天津医科大学肿瘤医院 用于治疗神经母细胞瘤的喹啉衍生物
CN117503743B (zh) * 2023-12-08 2024-04-16 南京鼓楼医院 一种nlrp3炎症小体抑制剂及其在制备预防或治疗细胞焦亡的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
JPS6210085A (ja) * 1985-07-05 1987-01-19 Yoshitomi Pharmaceut Ind Ltd トリフルオロメチルプリン誘導体
CN100345830C (zh) * 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
WO2005000404A2 (en) * 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
GB2431156A (en) * 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase

Also Published As

Publication number Publication date
CN101730697A (zh) 2010-06-09
BRPI0809140A2 (pt) 2014-08-26
WO2008116129A3 (en) 2009-02-12
CL2008000790A1 (es) 2008-05-30
CA2681326A1 (en) 2008-09-25
EP2125815A2 (en) 2009-12-02
MX2009010067A (es) 2009-10-12
JP2010522209A (ja) 2010-07-01
WO2008116129A2 (en) 2008-09-25
AU2008228758A1 (en) 2008-09-25
AR065813A1 (es) 2009-07-01
US20080233127A1 (en) 2008-09-25
TW200902531A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR
RU2018121834A (ru) Новое соединение бифенила или его соль
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
ECSP066829A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20140011A1 (es) Compuestos y composiciones novedosos para la inhibicion de nampt
EA200801828A2 (ru) Соединения 1,2,4,5-тетрагидро-3h-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
MX2012002059A (es) Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
PA8852101A1 (es) Nucleótidos uracil ciclopropílicos
AR063454A1 (es) Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas.
PE20151539A1 (es) Nuevos derivados de pirazol
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
AR066020A1 (es) Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1.
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7
AR051795A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
AR076850A1 (es) Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa.
DOP2010000022A (es) Derivados de pirimidina 934

Legal Events

Date Code Title Description
FA Abandonment or withdrawal